Sheet 1 of 3

Form PTO-1449	Docket Number 273012011120	Application Number 09/756,687	
ONFORMATION DISCLOSURE CITATION AN APPLICATION	Applicant		
AN APPLICATION	Patrick Mark CURRY, et al.		
MAY 0 7 2001 We several sheets if necessary)	Filing Date: April 21,2000	Group Art Unit 1646 /642	
		3R	
TRADEMARK.	<u> </u>		

## **U.S. PATENT DOCUMENTS**

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
SR	1.	12/1992	5,171,749	Levy et al.	514	410	\
Ī	2.	06/1999	5,929,105	Sternberg et al	514	410	
	3.	03/1984	4,436,727	Ribi	424	. 177	
·	4.	09/1989	4,866,034	Ribi	514	2	
	5.	03/1990	4,912,094	Myers et al.	514	54	
	6.	04/1990	4,920,143	Levy et al.	514	410	
	7.	11/1989	4,883,790	Levy et al.	540	145	\
	8.	03/1992	5,095,030	Levy et al.	514	410	
	9.	03/1999	5,880,145	Sternberg et al.	514	410	
	10.	05/1994	5,308,608	Dolphin et al.	424	9	
	11.	04/1995	5,405,957	Tang et al.	540	472	
	12.	04/1996	5,512,675	Tang et al.	540	472	
	13.	03/1998	5,726,304	Tang et al.	540	145	\
	14.	12/1992	5,171,741	Dougherty	514	185	
	15.	11/1998	5,831,088	Dolphin et al.	540	474	1.
	16.	12/1997	5,703,230	Boyle et al.	540	145	1
<b>→</b>	17.	03/1999	5,883,246	Bruckner et al.	540	145	

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	-Class	Subclass	Translation YES NO
SIR	18.	10/1996	WO 96/31237	WO			
+	19.	09/1999	WO 99/47162	wo			

OTHER DOCUMENTS (including author, title, Date, Pertinent Pages, Etc.

Examiner Initials	Ref. No.	Title	,				
ЕХАМП	NER:	1	2	<b></b>	DATE CONSIDERED:	6/5/03	
EVALOR					4	1. 1. 1.1	

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449			Docket Number 273012011120	Application Number 09/756,687			
INFORMATION DISCLOSURE CITATION		ON DISCLOSURE CITATION	Applicant				
70.	in an application		Patrick Mark CURRY, et al.				
MAY 0 7 2	الير الار	se several sheets if necessary)	Filing Date: April 21,2000	Group Art Unit 1646 /642			
<u>.</u>				3h			
TRADE!	APP						
5R	20.		J, Charrier K, Morris AE, Lee CC, Williams DE, Lyman SD gand in vivo in mice. Blood 88:2004-2012				
	21.	Burger, U.L., Chang, M.P., Nagoshi, M., Goedegebuure, P.S. and Eberlein, T.J. (1996) Improved in vivo efficacy of tumor-infiltrating lymphocytes after restimulation with irradiated tumor cells in vitro. <i>Annals of Surgical Oncology</i> , 3:580-587.					
	22.	Chen, W.R., Adams, R.L., Carubelli, I immunotherapy: a novel modality for o					
	23.	Chen, W.R. et al. (1998). Proc SPIE-L	NT SOCOPT ENG 3254:27-34.				
	24.	Cho, Y.H., Straight, R.C. and Smith, J.A., Jr. (1992) Effects of photodynamic therapy in combination with intravesical drugs in a murine bladder tumor model. <i>J Urol</i> , 147:743-6.					
	25.	Cox, J.C. and Coulter, A.R. (1997) Adjuvantsa classification and review of their modes of action. <i>Vaccine</i> , 15:248-56.					
	26.	Dougherty, T.J., Grindley, G.B., Fiel, R., Weishaupt, K.R. and Boyle, D.G. (1975) Photoradiation therapy. II. Cure of animal tumors with hematoporphyrin and light. <i>Journal of the National Cancer Institute</i> , 55:115-119.					
	27.	Esche C, Subbotin VM, Maliszewski C, Lotze MT, Shurin MR (1998) FLT3 ligand administration inhibits tumor growth in murine melanoma and lymphoma. <i>Cancer Res</i> 58:380-383.					
	28.	Evans, S., Matthews, W., Perry, R., Fraker, D., Norton, J. and Pass, H.I. (1990) Effect of photodynamic therapy on tumor necrosis factor production by murine macrophages. <i>Journal of the National Cancer Institute</i> , 82:34-39.					
	29.	Fingar, V.H., Wieman, T.J. and Doak, K.W. (1990) Role of thromboxane and prostacyclin release on photodynamic therapy-induced tumor destruction. <i>Cancer Research</i> , 50:2599-2603.					
	30.	Gore, M. and Riches, P. (1996) The history of immunotherapy. In Gore, M. and Riches, P. (eds.), Immunotherapy in cancer. John Wiley & Sons, Chichester, pp. 1-9.					
	31.	Granville, D.J., Levy, J.G. and Hunt, D.W. (1998) Photodynamic treatment with benzoporphyrin derivative monoacid ring A produces protein tyrosine phosphorylation events and DNA fragmentation in murine P815 cells. <i>Photochem Photobiol</i> , 67:358-62.					
	32. 🗸	Hartwell et al. (1997). Integrating Genetic Approaches into the Discovery of Anticancer Drugs.  Science 278:1064-1068.					
+	33.	Jacobsen SE, Okkenhaug C, Myklebust J, Veiby OP, Lyman SD (1995) The FLT3 ligand potently and directly stimulates the growth and expansion of primitive murine bone marrow progenitor cells in vitro: synergistic interactions with interleukin (IL) 11, IL-12, and other hematopoietic growth factors. J Exp Med 181:1357-1363.					
EXAMI	NER:	100	DATE CONSIDERED:	615/03			
		al if citation considered, whether or not the citation considered. Include a copy of this form with n		ine through the citation if not in			

				4 , Sheet 3 of 3			
Form PTO-1449			Docket Number 273012011120	Application Number 09/756,687			
INFORMATION DISCLOSURE CITATION		ON DISCLOSURE CITATION	Applicant				
O P P P P P P P P P P P P P P P P P P P		AN APPLICATION	Patrick Mark CURRY, et al.				
MAY 0 7 2001 W			Filing Date: April 21,2000	Group Art Unit 1946 / 1292			
	COUT E			5r			
Egy.	ato						
BARE!	34.	Jain. (1994). Barriers to Drug Deliver	ery in Solid Tumors. Sci Am 271(1):58-65.				
5R	St. Korbelick, M. et al. Proceedings of the International Conference on Photodynamic Therapy and Medical Laser Applications, XX,XX 24 JUne 1992, pages 518-520.						
	36.	Korbelik, M., Krosl, G. and Chaplin, D.J. (1993) Can PDT be potentiated by immunotherapy. <i>Proc. SPIE</i> , 1616:192-198.					
	37.	Korbelik M: Induction of tumor immu 14:329-334	unity by photodynamic therapy.	J Clin Laser Med Surg (1996)			
	38. <i>J</i>	Korbelik, M., Naraparaju, V.R. and Yamamoto, N. (1997) Macrophage-directed immunotherapy as adjuvant to photodynamic therapy of cancer. <i>British Journal of Cancer</i> , 75:202-7.					
	39.	Korbelik, M. and Cecic, I. (1998) Enhancement of tumour response to photodynamic therapy by adjuvant mycobacterium cell-wall treatment. <i>J Photochem Photobiol B</i> , 44:151-8.					
	40.	Krosl G, Korbelik M, Dougherty GJ: Induction of immune cell infiltration into murine SCCVII tumour by photofrin-based photodynamic therapy. <i>Br J Cancer</i> (1995) 71:549-555.					
	41.	Krosl, G. and Korbelik, M. (1994) Potentiation of photodynamic therapy by immunotherapy: the effect of schizophyllan (SPG). <i>Cancer Letters</i> , 84:43-49.					
	42.	Maraskovsky E, Brasel K, Teepe M, Roux ER, Lyman SD, Shortman K, McKenna HJ (1996) Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. <i>J Exp Med</i> 184:1953-1962.					
	43.	Myers, R.C., Lau, B.H., Kunihira, D.Y., Torrey, R.R., Woolley, J.L. and Tosk, J. (1989) Modulation of hematoporphyrin derivative-sensitized phototherapy with corynebacterium parvum in murine transitional cell carcinoma. <i>Urology</i> , 33:230-235.					
	44.	Nseyo, U.O., Whalen, R.K., Duncan, M.R., Berman, B. and Lundahl, S. (1989) Immune response following photodynamic therapy for bladder cancer. <i>Proceedings of the Society of Photo-Optical Instrumentation Engineers</i> , 1065:66-72.					
	, 45.	Section 3: Treatment of metastatic cancer to bone. In DeVita Jr., V.T., Hellman, S. and Rosenberg, S.A. (eds.), <i>Cancer: Principles and Practice</i> . J.B. Lippincott Company, Philadelphia, Vol. 2, pp. 2298-2317.					

EXAMINER: 1 P DATE CONSIDERED: 6/5/03

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.